Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 10, Octobre 2011
Page(s) 820 - 822
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20112710009
Publié en ligne 21 octobre 2011
  1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003 ; 3 : 459–465. [CrossRef] [PubMed] [Google Scholar]
  2. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007 ; 26 : 3113–3121. [CrossRef] [PubMed] [Google Scholar]
  3. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003 ; 4 : 111–120. [CrossRef] [PubMed] [Google Scholar]
  4. Dubus P. CDK4, cible thérapeutique des adénocarcinomes pulmonaires porteurs d’une mutation de l’oncogène KRAS. Med Sci (Paris) 2010 ; 26 : 1023–1025. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011 ; 19 : 652–663. [CrossRef] [PubMed] [Google Scholar]
  6. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004 ; 22 : 4456–4462. [CrossRef] [PubMed] [Google Scholar]
  7. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010 ; 5 : 1630–1636. [CrossRef] [PubMed] [Google Scholar]
  8. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010 ; 16 : 2450–2457. [CrossRef] [PubMed] [Google Scholar]
  9. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006 ; 66 : 9483–9491. [CrossRef] [PubMed] [Google Scholar]
  10. Ehrenreiter K, Kern F, Velamoor V, et al. Raf-1 addiction in ras-induced skin carcinogenesis. Cancer Cell 2009 ; 16 : 149–160. [CrossRef] [PubMed] [Google Scholar]
  11. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011 ; 19 : 11–15. [CrossRef] [PubMed] [Google Scholar]
  12. Hatzivassiliou G. Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464 : 431–435. [CrossRef] [PubMed] [Google Scholar]
  13. Bollag G, Hirth P,Tsai J,, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010 ; 467 : 596–599. [CrossRef] [PubMed] [Google Scholar]
  14. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 ; 363 : 809–819. [CrossRef] [PubMed] [Google Scholar]
  15. Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010 ; 18 : 63–73. [CrossRef] [PubMed] [Google Scholar]
  16. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009 ; 462 : 104–107. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.